araag2/HINT huggingface dataset:
Clinical trial NCT03469947 (phase 3, status: unknown status)
Conditions: hemorrhagic shock, trauma injury
ICD codes: A91, A96.0, A96.1, A98.1, D47.3, D69.9, I78.0
Drugs: tranexamic acid
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Blunt or penetrating trauma with signs and symptoms of hemorrhagic shock

          -  Systolic blood pressure less than 90 mmHg at scene of injury, during air and/or ground
             medical transport, or on arrival to designated trauma centers

          -  Any sustained blunt or penetrating injury within 3 hours

          -  Patient who are considered to be at high risk for significant hemorrhage

               1. Estimated blood loss of 500 milliliters int he field accompanied with HR >120

               2. Bleeding not controlled by direct pressure or tourniquet

               3. Major amputation of any extremity above the wrists and above the ankles

        Exclusion Criteria:

          -  Any patient under 18 years of age

          -  Any patient with an active thromboembolic event (within the last 24 hours) i.e. active
             stroke, myocardial infarction, or pulmonary embolism

          -  Any patient with a hypersensitivity or anaphylactic reaction to TXA

          -  Any patient more than 3 hours post injury

          -  Traumatic arrest with > 5 minutes CPR without return of vital signs

          -  Penetrating cranial injury

          -  Traumatic brain injury with brain matter exposed

          -  Isolated drowning or hanging victims

          -  Documented cervical cord injury with motor deficit
Clinical trial NCT03493568 (phase 3, status: unknown status)
Conditions: hiv-1-infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: genvoya 150mg-150mg-200mg-10mg tablet, dolutegravir 50 mg plus one rti
SMILES: [H][C@@](CO)(C(C)C)N1C=C(C(O)=O)C(=O)C2=C1C=C(OC)C(CC1=C(F)C(Cl)=CC=C1)=C2, N[C@@H](CO)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age >18 years

          2. Willing and able to provide informed consent

          3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI

          4. HIV-RNA <50 copies/mL since at least 6 months

        Exclusion Criteria:

          1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic
             chemotherapy)

          2. Serious illness requiring systemic treatment and/or hospitalization

          3. Current use of immunomodulant or immunosuppressive drugs

          4. Need (or will likely need) of treatment with antacids

          5. Use of drugs contraindicated with study drugs, according to technical sheets

          6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous
             resistance tests (patients with the 184I/V mutation alone are allowed to enter the
             study)

          7. Resistance or previous virological failure to InSTIs

          8. Detectable HCV-RNA

          9. Documented allergy to COBI or EVG or FTC or tenofovir.

         10. Absolute neutrophil count (ANC) <500/µL

         11. Haemoglobin <8.0 g/dL

         12. Platelet count <50,000/µL

         13. eGFR <30 mL/min/1.73m2 by CKD-EPI equation

         14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)

         15. Presence of Child Pugh Class B or C liver cirrhosis.

         16. Pregnancy or breastfeeding

         17. Woman of childbearing potential who does not agree to adopt highly effective
             contraception.
Clinical trial NCT03525444 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-445/tez/iva, iva, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Heterozygous for the F508del mutation (F/MF)

          -  Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for
             age, sex, and height

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  Solid organ or hematological transplantation

        Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT03525548 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-445/tez/iva, tez/iva, iva, placebo, placebo
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Homozygous for the F508del mutation (F/F)

          -  Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for
             age, sex, and height

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  Solid organ or hematological transplantation

        Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT03559062 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tez/iva, iva, placebo, placebo
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Homozygous for F508del or heterozygous for F508del and an RF mutation (as defined in
             the protocol).

          -  Participants with ppFEV1 of ≥70 percentage points adjusted for age, sex, height.

          -  Participants with a screening LCI2.5 result ≥7.5.

          -  Participants who are able to swallow tablets.

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension.

          -  Colonization with organisms associated with a more rapid decline in pulmonary status.

          -  Solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03559257 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: galcanezumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of migraine or chronic migraine.

          -  History of migraine headaches at least 1 year prior to screening, with onset prior to
             age 50.

          -  History of at least 4 migraine headache days and at, with at least 1 headache-free day
             per month on average within the past 3 months.

          -  Have documentation of 2 to 4 migraine preventive medication category failures due to
             inadequate efficacy or tolerability, in the past 10 years.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to galcanezumab or another calcitonin gene-related
             peptide (CGRP) antibody.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine).

          -  Pregnant or nursing.
Clinical trial NCT03573908 (phase 3, status: completed)
Conditions: irritable bowel syndrome characterized by constipation
ICD codes: B09, B08.8
Drugs: linaclotide, placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has no clinically significant findings on a physical examination and clinical
             laboratory tests

          -  Female patients of childbearing potential must agree to use one of the following
             methods of birth control:

               1. Hormonal contraception

               2. Double-barrier birth control

               3. Maintenance of a monogamous relationship with a male partner who has been
                  surgically sterilized by vasectomy

          -  Patient meets protocol criteria for diagnosis of IBS-C

          -  Patient demonstrates continued IBS-C symptoms through Pretreatment Period

          -  Patient maintains a minimum level of compliance with daily diary

        Exclusion Criteria:

          -  Patient has history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with a medical condition that may contribute
             to abdominal pain

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments
Clinical trial NCT03575871 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: pf-04965842 100 mg, pf-04965842 200 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  12 years of age or older with a minimum body weight of 40 kg

          -  Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate
             to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS
             severity 4)

          -  Recent history of inadequate response or inability to tolerate topical AD treatments
             or require systemic treatments for AD control

        Exclusion Criteria:

          -  Unwilling to discontinue current AD medications prior to the study or require
             treatment with prohibited medications during the study

          -  Prior treatment with JAK inhibitors

          -  Other active nonAD inflammatory skin diseases or conditions affecting skin

          -  Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q
             wave interval abnormalities, current or history of certain infections, cancer,
             lymphoproliferative disorders and other medical conditions at the discretion of the
             investigator

          -  Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
             to use contraception
Clinical trial NCT03582007 (phase 3, status: terminated)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: murepavadin, one anti-pseudomonal antibiotic
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Reason stopped: 
    safety data review
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subject has received mechanical ventilation for at least 48h at the time of the
             randomisation OR at least 2 of the following signs or symptoms presenting within 24
             hours prior to randomization: New onset of cough or worsening of baseline cough and/or
             dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned
             respiratory secretion characterized by purulent appearance indicative of bacterial
             infection or a worsening in character of purulent appearance

          -  Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within
             24h prior to randomization

          -  Presence of new or progressive infiltrate on chest X-ray

          -  Presence of clinical criteria consistent with Pneumonia

          -  Strong clinical suspicion of pneumonia due to P. aeruginosa

        Key Exclusion Criteria:

          -  Known or suspected community-acquired bacterial pneumonia or viral, fungal, or
             parasitic pneumonia

          -  known hypersensitivity to any component of ertapenem, meropenem or to other drugs in
             the same class or demonstrated anaphylactic reactions to beta-lactams or a history of
             allergic reactions to any of the penicillins, cephalosporins, or β-lactamase
             inhibitors

          -  Severe liver or renal impairment

          -  Expected survival < 72 hours

          -  Evidence from an available surveillance culture of co infection with ertapenem ,
             meropenem or piperacillin tazobactam resistant Gram negative pathogen(s)

          -  Women who are pregnant or nursing
Clinical trial NCT03629184 (phase 3, status: completed)
Conditions: influenza
ICD codes: J11.81, J11.82, J10.01, J10.81, J10.82, J11.08, J11.2
Drugs: baloxavir marboxil, oseltamivir
SMILES: [H][C@@]12COCCN1C(=O)C1=C(OCOC(=O)OC)C(=O)C=CN1N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C12, CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 1 to < 12 years at randomization (Day 1).

          -  Written informed consent/assent for study participation obtained from participant's
             parents or legal guardian, with assent as appropriate by the participant, depending on
             the patient's level of understanding

          -  Participant able to comply with study requirements, depending on the patient's level
             of understanding

          -  Participant with a diagnosis of influenza virus infection confirmed by the presence of
             all of the following:

          -  Fever ≥ 38 degree celsius (tympanic temperature) at screening

          -  At least one respiratory symptom (either cough or nasal congestion)

          -  The time interval between the onset of symptoms and screening is ≤ 48 hours

        Exclusion Criteria:

          -  Severe symptoms of influenza virus infection requiring inpatient treatment

          -  Concurrent infections requiring systemic antiviral therapy at screening

          -  Require, in the opinion of the investigator, any of the prohibited medication during
             the study

          -  Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine
             within 2 weeks prior to screening

          -  Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to
             randomization

          -  Concomitant treatment with steroids or other immuno-suppressant therapy

          -  Known HIV infection or other immunosuppressive disorder

          -  Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes,
             thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or
             participants with known chronic renal failure.

          -  Active cancer at any site

          -  History of organ transplantation

          -  Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to
             acetaminophen

          -  Females with child-bearing potential

          -  Participation in a clinical trial within 4 weeks or five half-lives of exposure to an
             investigational drug prior to screening, whichever is longer
Clinical trial NCT03688711 (phase 3, status: completed)
Conditions: hypoglycemia, diabetes mellitus, type 1
ICD codes: E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, E10.649, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: dasiglucagon, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined
             by the American Diabetes Association (3).

          -  Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
             (defined as no more than a 10-unit daily variation in total daily insulin dose) 30
             days prior to screening

          -  Hemoglobin A1c <10%.

          -  Aged between 18 and 75 years, both inclusive.

        Exclusion Criteria:

          -  Previous participation in a clinical trial within the dasiglucagon in the rescue
             treatment of hypoglycemia program.

          -  Known or suspected allergy to trial drug(s) or related products.

          -  History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).

          -  Previous participation in this trial. Participation being defined by signing the
             informed consent document.
Clinical trial NCT04341727 (phase 3, status: suspended)
Conditions: coronavirus infection
ICD codes: B34.2
Drugs: hydroxychloroquine sulfate, azithromycin, chloroquine sulfate
SMILES: CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O, CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
Reason stopped: 
    dsmb recommended study suspension slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalization for management of SARS CoV-2 infection

          -  Positive SARS CoV-2 test

          -  Age >=18 years

          -  Provision of informed consent

          -  Electrocardiogram (ECG) ≤48 hours prior to enrollment

          -  Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive
             metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.

          -  If participating in sexual activity that could lead to pregnancy, individuals of
             reproductive potential who can become pregnant must agree to use contraception
             throughout the study. At least one of the following must be used throughout the study:

               -  Condom (male or female) with or without spermicide

               -  Diaphragm or cervical cap with spermicide

               -  Intrauterine device (IUD)

               -  Hormone-based contraceptive

        Exclusion Criteria:

          -  Contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin

          -  Current use hydroxychloroquine, chloroquine or azithromycin

          -  Concurrent use of another investigational agent

          -  Invasive mechanical ventilation

          -  Participants who have any severe and/or uncontrolled medical conditions such as:

               -  unstable angina pectoris,

               -  symptomatic congestive heart failure,

               -  myocardial infarction,

               -  cardiac arrhythmias or know prolonged QTc >470 males, >480 female on ECG

               -  pulmonary insufficiency,

               -  epilepsy (interaction with chloroquine),

          -  Prior retinal eye disease

          -  Concurrent malignancy requiring chemotherapy

          -  Known Chronic Kidney disease, eGFR<10 or dialysis

          -  G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment

               -  Known Porphyria

               -  Known myasthenia gravis

               -  Currently pregnant or planning on getting pregnant while on study

               -  Breast feeding

               -  AST/ALT >five times the upper limit of normal ULN*

               -  Bilirubin >five times the ULN*

               -  Magnesium <1.4 mEq/L*

               -  Calcium <8.4mg/dL >10.6mg/dL*

               -  Potassium <3.3 >5.5 mEg/L*